The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital announced topline results from Regimen F of the HEALEY ALS Platform Trial evaluating fosigotifator (ABBV-CLS-7262) in people… More >>

The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital announced topline results from an analysis of Regimen G evaluating DNL343, an eIF2B agonist developed by Denali… More >>

Corcept Therapeutics, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol,… More >>

– Study failed to meet primary and secondary efficacy endpoints – PTC Therapeutics announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing… More >>

Biogen published Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study Background Hexanucleotide… More >>

uniQure, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial… More >>

Amylyx’s ill fated treatment for amyotrophic lateral sclerosis, was approved for marketing by the US Food and Drug Administration but rejected by the European Medicines Agency. The Pink Sheet explores… More >>

Biogen announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY® (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS)… More >>